The operation is one of two – the other located in France – that is being divested under an agreement between both firms that was announced in January.
The capital site produces capsules for pharmaceutical and consumer health and nutrition applications.
Lonza said a “seamless ownership transfer process remains a priority”.
Gordon Bates, president and head of small molecules at Lonza, said: “The strategic divestment of our Ploermel [France] and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimise existing expertise and technologies.
“In this context, as we close the divestment process, we are confident that NextPharma is well placed to develop and grow both sites to their full potential. We wish to thank the leadership teams and employees at the Ploermel and Edinburgh sites for their continuing dedication and professionalism during the transition period.”
Peter Burema, chief executive of NextPharma, said: “We are very excited at adding two new centres of excellence, at Ploermel and Edinburgh, to NextPharma’s manufacturing network, allowing us to further broaden our technology offering for both our existing and new customers.
“These technologies, combined with the know-how and expertise of the employees at both sites, will provide additional solutions for drug formulations which will benefit patients across the world.”
Founded in 1897 in the Swiss Alps, Lonza operates across five continents and has some 14,000 full-time employees. NextPharma has a footprint spanning sites in Germany, France, Finland and now Scotland.